Rapid Detection of
            <i>Trypanosoma cruzi</i>
            in Human Serum by Use of an Immunochromatographic Dipstick Test

Reithinger, Richard; Grijalva, Mario J.; Chiriboga, Rosa F.; Noya, Belkisyolé Alarcón de; Torres, Jaime R.; Pavía-Ruz, Norma; Manrique-Saide, Pablo; Cardinal, Marta Victoria; Gürtler, Ricardo E.

doi:10.1128/jcm.02474-09

Cited by 26 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The performance data for the Trypanosoma Detect Rapid test (93.5% sensitivity and 95.2% specificity) are close to the data reported in 2010 by Reithinger et al (38) and in other similar studies (39). The SD-Bioline Chagas Ab Rapid test and the OnSite Chagas Ab Rapid testcassette results in serum were low compared to those reported in 2009 (40).…”

Section: Discussionsupporting

confidence: 86%

Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity

et al. 2014

View full text Add to dashboard Cite

; Universidad Antonio Nariño (UAN), Bogotá, Colombia o Chagas disease is one of the main public health issues in Latin America. Increasingly during the past few decades, Trypanosoma cruzi infection has been detected in North America, Europe, and the Western Pacific, mainly as a result of population movement. The limited availability of rapid serological diagnostic tests hinders rapid diagnosis and early treatment in areas of endemicity and nonendemicity. In collaboration with 11 national reference laboratories (NRLs) from different geographical areas, we evaluated the performances of commercialized serological rapid diagnostic tests (RDT) for T. cruzi infection. Eleven commercialized T. cruzi infection RDTs were evaluated on a total of 474 samples extensively tested with at least three different techniques for Chagas disease, maintained at controlled low temperatures, and stored in the serum banks of the 11 NRLs. We measured the sensitivity, specificity, and concordance of each RDT and provided an additional questionnaire to evaluate its ease of use. The selected RDTs in this study were performed under controlled laboratory conditions. Out of the 11 RDTs, we found 8 of them to be useful, with the cassette format favored over the strip. We did not observe significant differences in RDT performances in the different regions. Overall, the performance results were lower than those disclosed by the manufacturers. The results of this evaluation validate the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment at a primary health care facility for patients who are willing to be treated. Further studies should be conducted in the laboratory and in the field to confirm these data, expressly to evaluate reproducibility in resource-limited settings, or using whole blood in clinical settings in areas of endemicity and nonendemicity.

show abstract

Section: Discussionsupporting

confidence: 86%

Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These screening tests are quickly performed, but they have not been validated at large scale and need confirmation with standard serological tests [15], [16].…”

Section: Diagnostic Methodsmentioning

confidence: 99%

Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women

et al. 2011

View full text Add to dashboard Cite

“…The fact that many of them emerged from independent screenings carried out in different laboratories further supported their diagnostic potential but, unfortunately also led to a confusing nomenclature that still persist (Table 1) (reviewed in (da Silveira, Umezawa and Luquetti, 2001; Frasch et al, 1991)). Some of the antigens included in the T. cruzi 'parental repertoire' were extensively validated, in certain cases by way of multicenter trials (Caballero et al, 2007; Reithinger et al, 2010), and set the stage for the development of second-generation Chagas disease diagnostic methods. A variety of antigen expression procedures (i.e.…”

Section: Diagnostic Applications For Chagas D Isease: Present Knowledgementioning

confidence: 99%

“…These may be either qualitative or semi-quantitative and are characterized by the delivery of quick results, in most cases without the need for electrical equipment. In the case of Chagas disease, several LFIAs based on antigenic fractions or recombinant antigens and a single PoC test aimed at the capture and concentration of T. cruzi TESA antigens in urine samples (Chunap, see above) were developed (Table 1) (Castro-Sesquen et al, 2014; Houghton et al, 2009; Reithinger et al, 2010). Serological tests, however show substantial variations in their sensitivity in different geographical areas (Verani et al, 2009), and display sub-optimal performances (Sanchez-Camargo et al, 2014).…”

Section: Diagnostic Applications For Chagas D Isease: Pending Issuesmentioning

confidence: 99%

Chagas Disease Diagnostic Applications

Balouz

Agüero

Buscaglia

2017

Advances in Parasitology

View full text Add to dashboard Cite

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long and debilitating illness of major significance throughout Latin America, and an emergent threat to global public health. Being a neglected disease, the vast majority of Chagasic patients have limited access to proper diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine development. In this context, identification of novel biomarkers able to transcend the current limits of diagnostic methods surfaces as a main priority in Chagas disease applied research. The expectation is that these novel biomarkers will provide reliable, reproducible and accurate results irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-associated features of Chagasic populations. In addition, they should be able to address other still unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid assessment of treatment efficiency or failure, indication/prediction of disease progression and direct parasite typification in clinical samples. The lack of access of poor and neglected populations to essential diagnostics also stress the necessity of developing new methods operational in Point-of-Care (PoC) settings. In summary, emergent diagnostic tests integrating these novel and tailored tools should provide a significant impact on the effectiveness of current intervention schemes and on the clinical management of Chagasic patients. In this chapter, we discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, as well as the opportunity provided by recent advances in high-throughput methods for biomarker discovery.

show abstract

Rapid Detection of Trypanosoma cruzi in Human Serum by Use of an Immunochromatographic Dipstick Test

Cited by 26 publications

References 25 publications

Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity

Comparative Evaluation of 11 Commercialized Rapid Diagnostic Tests for Detecting Trypanosoma cruzi Antibodies in Serum Banks in Areas of Endemicity and Nonendemicity

Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women

Chagas Disease Diagnostic Applications

Contact Info

Product

Resources

About